CGRP & Gepants: What We Know and What to Expect

We are more than a year out from the release of the first CGRP antagonist for the treatment of migraine, but just how well is this class of medications working? In this episode, we interview headache specialist, Dr. Merle Diamond to get an update on efficacy and what we can expect in the coming year as a new group of these medications are released.

This podcast is sponsored in part by Amgen/Novartis.

*The contents of this podcast are intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The speaker does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

[NationalHeadacheFoundation]

Thank you for this excellent discussion with Dr. Merle Diamond.

[NationalHeadacheFoundation]

Thank you, Dr. Diamond, for sharing this helpful information.

[BikesBlades]

I participated in the phase-3 clinical trial for Atogepant, then rolled over into the open-label study, and it has been extremely effective.